Repair Biotechnologies’ REP-0004 mRNA therapy gains FDA orphan drug designation and demonstrates rapid plaque regression in mouse models, potentially revolutionizing cardiovascular care. An mRNA...
First-in-human trial shows Cyclarity’s UDP-003 can safely bind and excrete 7-ketocholesterol, potentially reversing atherosclerosis. Cyclarity Therapeutics’ UDP-003 achieves first safe removal...
UDP-003, a cyclodextrin-based drug, safely reduces 7-ketocholesterol in Phase 1, potentially reversing atherosclerosis instead of just slowing it. A novel drug that removes toxic cholesterol byproduct...
Recent research reveals how mitochondrial decline accelerates cellular senescence in blood vessels, driving conditions like atherosclerosis and blood-brain barrier leakage, with emerging therapies tar...
New research identifies IRF7 as a critical driver of unstable atherosclerotic plaques, offering a potential therapeutic target to reduce cardiovascular events through innovative clinical trials and te...
Recent studies confirm periodontal disease elevates cardiovascular risk through inflammation, with 2023 findings showing direct bacterial invasion of arteries. This analysis explores mechanisms and pr...
A new study demonstrates that CAR regulatory T cells targeting oxidized LDL can cut atherosclerotic plaque by 70% in mice, offering a potential one-time therapy for cardiovascular disease prevention. ...
Recent research highlights how neutrophil extracellular traps (NETs) drive chronic inflammation and vascular aging, with NET inhibitors like DNase I and PAD4 antagonists showing potential in reducing ...
Recent research shows neutrophil extracellular traps accelerate vascular aging by promoting inflammation and endothelial damage, with NET inhibitors offering promising anti-aging therapies for cardiov...
Excessive neutrophil extracellular traps (NETs) promote chronic inflammation and endothelial dysfunction, increasing risks for atherosclerosis and stroke, with recent research highlighting inhibitors ...